of GBM cases, including amplification and/or mutations in the EGFR gene (encoding epidermal growth factor receptor) and in the PDGFRA gene (encoding platelet-derived growth factor receptor-α). 3, 4 Numerous therapies targeting RTK signaling have been developed and tested in clinical trials and have shown varying levels of success. 5 The BMP family of growth factors has been proposed as potential non-cytotoxic therapeutic agents for inhibiting the growth of GIC by inducing differentiation 6 and sensitization to temozolomide. 7 BMP signaling promotes the differentiation of GIC by BMP type I receptors and the intracellular signaling pathway. 8, 9 Moreover, our previous study showed that BMP-4 and BMP-7 induce apoptosis by activating the BMP type I receptor ALK-2. 9 Although the BMP signaling pathway can be activated in GIC, some cells are resistant to BMP-induced differentiation or growth inhibition. 8, 10 Similarly, some GIC are refractory to BMP-induced apoptosis. We hypothesized that resistance to BMP-ALK-2-induced apoptosis in GIC is related to RTK activity given their major role in causing the resistance of cancer cells to cell death and growth inhibition. 11 Erythropoietin-producing hepatocellular carcinoma receptor A6 belongs to the Eph receptor family, which constitutes the largest family among RTK and is subdivided into EphA and EphB receptors. 12 Eph receptors form large signaling clusters, which is facilitated by binding to Eph receptor-interacting protein (ephrin) ligands on neighboring cells, thus activating both forward and reverse signaling. Eph signaling regulates cell adhesion, repulsion, differentiation, cytokinesis, cell survival, and apoptosis during development and tissue homeostasis. 12, 13 Eph receptors can also signal independently of ephrin binding and kinase activity. In GBM, EPHA2 and EPHA3 were reported to ligand-independently increase stemness, proliferation, and radiation resistance. 14, 15 In a ligand-dependent method, EPHA2 receptor is downregulated and dephosphorylated at Ser897 by ephrin-A1-Fc, thus forming a less invasive GBM tumor with growth inhibition. 14, 16 Targeting antibodies against EPHA2 and EPHA3 also blocked oncogenic effects of EPHA2 and EPHA3, and suppressed tumorigenesis. 17, 18 Additional studies implicate EPHA4, 19 EPHA5, 20 and EPHA7 21 as glioma promoters. However, little is known about the role of EPHA6 in GBM.
To evaluate whether BMP-ALK-2 modulates RTK activity in GIC apoptosis, we carried out a phospho-RTK screening array. We found that tyrosine phosphorylation of EPHA6 was upregulated after BMP-2 treatment in GIC expressing endogenous ALK-2. EPHA6 gain-of-function together with BMP-2 stimulation resulted in apoptosis in GIC that were resistant to BMP-2-induced cell death. Mechanistically, EPHA6 physically interacted with the ALK-2 receptor, whereas EPHA6 kinase activity was dispensable. Our data show that the cooperation of EPHA6 with BMP-2 signaling inhibits the tumorigenicity of GBM, which could serve as a potential therapeutic target or biomarker.
| MATERIAL S AND ME THODS

| Cell culture and cell viability
TGS-01, TGS-03, TGS-04, and TGS-05 cells are grade IV glioblastoma cells derived from surgically resected GBM tumors. 22 The cells were maintained under neurosphere culture conditions as described previously. 9, 22, 23 Briefly, the medium consisted of DMEM/F12 supplemented with Glutamax, B27 supplement, 15 μg/mL human recombinant insulin (all from Gibco, Thermo Fisher Scientific), 6 mg/mL D-(+)-glucose (Sigma-Aldrich, Merck), 20 ng/mL epidermal growth factor, and 20 ng/mL basic fibroblast growth factor (both from Peprotech).
Cell viability assay was evaluated using a WST-8 kit (Nacalai Tesque).
| Ligand and recombinant proteins
Recombinant human BMP-2 was a gift from Bioventus LLC. BMP-2 was given at 100 ng/mL in the experiments unless otherwise indicated. Recombinant human EPHA6-Fc and IgG1-Fc were procured from R&D Systems (Bio-Techne).
| Tyrosine phosphorylation screening
TGS-01, TGS-04, and TGS-05 cells were incubated with 100 ng/ mL BMP-2 for 24 hours prior to cell lysis. Phosphorylated proteins were assessed using a human phospho-RTK array kit (ary001b and ary003b; R&D Systems). Samples were processed according to the manufacturer's protocol.
| Plasmid construction and adenovirus production
Adenovirus for LacZ (ad-LacZ) and constitutively active (CA) kinase ALK-2 QD (mutation at the Gly-Ser domain, Q207D) (ad-ALK-2-CA) vectors were described previously. 24 Human EPHA6 (accession NP_001073917.2) was amplified by PCR. C-terminally FLAG-tagged full-length human EPHA6 cDNA was cloned into an adenoviral vector (ad-EPHA6-WT) as previously described. 9 The EPHA6 K757R mutant was constructed using a mutagenesis primer 5′-GTTGCCATTAGAACTTTGAAA-3′ and cloned into the adenoviral vector (ad-EPHA6-KD). The mutation site was based on the corresponding kinase-dead mutant of EPHA8 K666M 25 and EPHA3 K653R. 26 All sequences were confirmed by Sanger sequencing analysis. For in vitro experiments, ad-ALK-2-CA was infected at multiplicity of infection (MOI) 30. Ad-EPHA6-WT and ad-EPHA6-KD were infected at MOI 120 in TGS-03 and TGS-04 cells, and at MOI 60 in TGS-01 cells. The corresponding MOI for ad-LacZ was used as a control.
| Immunoblotting and coimmunoprecipitation
The lysis buffer consisted of 1% Nonidet P-40, 150 mmol/L NaCl, 20 mmol/L Tris-HCl (pH 7.5), cOmplete EDTA-free protease inhibitor cocktail (Roche Life Science) and phosphatase inhibitor cocktail (Nacalai Tesque). For coimmunoprecipitation, 0.5 mL cell lysate was incubated with 25 or 30 μL precoated Dynabeads protein A or M280 sheep antimouse IgG (both from Invitrogen, Thermo Fisher Scientific), respectively, overnight or for 6 hours at 4°C with gentle rotation. Dynabeads were precoated with 2 μg primary antibody per sample. Samples were washed four times with lysis buffer and eluted in SDS-PAGE loading buffer at 95°C for 3 minutes. Immunoblotting was carried out as previously described. 9
| Flow cytometry
Single cell suspensions were stained with Annexin-V-APC and propidium iodide (eBioscience, Thermo Fischer Scientific) for 15 minutes at room temperature before detection using a Gallios (Beckman Coulter) flow cytometer. Results were analyzed with Flow Jo software (TreeStar).
| Tumor orthotopic transplantation assay and in vivo bioluminescence imaging
TGS-01 cells expressing luciferase were transduced with adenovirus to express LacZ (ad-LacZ), EPHA6 WT (ad-EPHA6-WT), or EPHA6 kinase-dead mutant (ad-EPHA6-KD) (MOI 60) together with pretreatment with 200 ng/mL BMP-2 for 2 days prior to intracranial injection in 6-week-old female BALB/c nude mice (Sankyo Labo Service). A total of 75 000 cells in 3 μL medium was stereotactically injected over a 1-minute period. Injection coordinates, imaging, and killing methods were conducted as previously described. 9, 27 Log-rank test was used for statistical analysis.
| Phylogenetic tree of EphA kinase domain
Amino acid sequences of the kinase domains of human EPHA1-8 were obtained from the NCBI protein database (www.ncbi.nlm.nih. gov). The sequences were aligned with Clustal Omega (www.clustal. org/omega) 28 
| Patient survival and EPHA6 expression analysis
For EPHA6 expression analysis, microarray data from the REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT) and TCGA were extracted from Project Betastasis (http://www.betas tasis.com). To analyze patient datasets from TCGA Pan-Cancer clinical data, 29 Z-scored expression values of mRNA were obtained from cBioPortal 30, 31 in April 2019. Patients were divided into tertiles based on their mRNA expression levels. Differences between groups were evaluated by the log-rank test using the R package cmprsk as described previously. 9,32
| Statistical analysis
Analysis of variance followed by Tukey-Kramer post-hoc test using GraphPad Prism 6 (GraphPad, Inc.) was carried out to determine the P-values and significance is shown in the figures. 
| Study approval
| Accession numbers
Raw RNA-seq data of patient-derived glioma cells are available at the DDBJ Japanese Genotype-phenotype Archive for genetic and phenotypic human data 33 with accession no. JGAS00000000077.
Detailed methods are available in Doc S1.
| RE SULTS
| EPHA6 is a putative GBM tumor suppressor that sensitizes GIC to BMP-induced apoptosis
To explore the potential mechanisms of BMP-ALK-2-induced apoptosis, we assessed phosphorylation of RTK affected by BMP type I receptor activity. We used three GIC cells: TGS-01 and TGS-04 cells expressing higher relative expression of ACVR1 (encoding ALK-2 protein), 9 and TGS-05 cells expressing lower levels of ACVR1 ( Figure   S1A ). These cells were then subjected to a protein array assay to detect phosphorylation changes in 49 RTK before and after BMP-2 stimulation ( Figure S1B ). Phosphorylation was downregulated by BMP-2 in the majority of the screened RTK (Table S1 ). EPHA6 was the only RTK in the array where phosphorylation was upregulated by BMP-2 in both TGS-01 and TGS-04 cells but not in TGS-05 cells ( Figure 1A and Table S1 ), indicating that EPHA6 is potentially activated by BMP-2 signaling in ALK-2-expressing cells.
We next evaluated whether EPHA6 is relevant in a larger population of glioma. Database analysis indicated that compared to the normal brain, EPHA6 mRNA expression is significantly lower in all four major GBM subtypes (classical, neural, proneural, and mesenchymal 34 ) ( Figure 1B ) and in other types of glioma such as astrocytoma and oligodendroglioma ( Figure S1C ). Moreover, high EPHA6 expression was significantly correlated with longer disease-free survival of patients with GBM ( Figure 1C ). These results indicate that EPHA6 may be a putative tumor suppressor and its activity could be modulated by BMP-2.
As a result of low levels of EPHA6 expressed in GBM and to investigate the potential role of EPHA6 as a BMP-2-induced tumor suppressor, we examined the function of this gene by increasing its expression through adenoviral transduction in TGS-03 and TGS-04 cells. These cells responded to BMP-induced phosphorylation of SMAD1/5 9 (data not shown; see Figure 2A ); however, they are relatively resistant to both BMP-2-induced cytostasis and apoptosis ( Figure S1D ). BMP induced apoptosis in TGS-04 cells at early passages, 9 
| Bone morphogenetic protein signaling regulates EPHA6 tyrosine phosphorylation
Consistent with the phospho-array results, EPHA6 overexpression and BMP-2 stimulation increased tyrosine phosphorylation of EPHA6 in TGS-03 and TGS-04 cells (Figure 2A ). To detect EPHA6 tyrosine phosphorylation, we used a phospho-EPHA antibody that recognizes tyrosine-779 phosphorylation of EPHA3. 26 Because of sequence homology, the antibody cross-reacts with other EPHA at the corresponding sites including EPHA6 (Y925) ( Figure 2B ). 35 Consistently, foretinib diminished EPHA6 phosphorylation in TGS-03 and TGS-01 cells overexpressing EPHA6, whereas dasatinib did not ( Figures 2D and S1G) . These results further confirm that the phospho-EPHA signal detected represented EPHA6 tyrosine phosphorylation rather than phosphorylation of EPHA2 or EPHA3.
Interestingly, the EPHA6 kinase domain has the closest homology to that of EPHA8 ( Figure 2E ). EPHA8 induces neuronal-like differentiation by sustained MAPK activation in murine glioma-neuroblastoma hybrid cells without the requirement for ephrin binding or kinase activity. 25 Thus, we investigated whether EPHA6 kinase activity is required for BMP-2-induced apoptosis.
| EPHA6 and BMP receptor kinase activities are differentially required for apoptosis
To assess the role of EPHA6 kinase activity in GIC apoptosis, we introduced a kinase dead (KD) mutant of EPHA6 (K757R). In both TGS-03 and TGS-04 cells, EPHA6 tyrosine phosphorylation was abolished when the KD mutant of EPHA6 was expressed, clearly contrasting the results for WT EPHA6 ( Figure 3A) . Apoptosis assays were carried out to compare EPHA6-WT and EPHA6-KD. Both F I G U R E 2 Bone morphogenetic protein 2 (BMP-2) induces erythropoietin-producing hepatocellular carcinoma receptor A6 (EPHA6) tyrosine phosphorylation. A, Immunoblot analysis of TGS-03 cells (left) and TGS-04 cells (right) infected with ad-LacZ or wild-type EPHA6 (ad-EPHA6-WT) with or without BMP-2 stimulation for 24 h. Cell lysates were subjected to immunoprecipitation (IP) with anti-FLAG antibody for EPHA6, followed by phospho-tyrosine or FLAG immunoblotting. pTyr, phospho-tyrosine; pSMAD1/5, phospho-SMAD1/5; TCL, total cell lysate. B, Amino acid sequence in the conserved activation loop region of EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, and EPHA8. The tyrosine residue recognized by phospho-EPHA (pEPHA) antibody when phosphorylated is highlighted in yellow (Y779 for EPHA3 and Y925 for EPHA6). C, Immunoblots of TGS-03 cells infected with ad-LacZ or ad-EPHA6-WT and treated or untreated with BMP-2 and 0.5 μmol/L LDN193189 for 24 h. Cell lysates were subjected to IP with FLAG antibody, followed by phospho-EPHA or FLAG immunoblotting. D, Immunoblots of TGS-03 cells infected with ad-EPHA6-WT, and treated with or without BMP-2, DMSO control or 1 μmol/L inhibitors for 24 h as indicated. LDN193, LDN193189; Dasa, dasatinib; Fore, foretinib; pSrc, phospho-Src. E, Phylogenetic tree of the kinase domain of the EPHA receptors WT and the KD mutant of EPHA6 induced apoptosis, which was enhanced in the presence of BMP-2 treatment ( Figure 3B Figure 3E ).
| EPHA6 physically interacts with BMP type I receptor ALK-2
To further characterize the mechanism of EPHA6 cooperation with ALK-2, we investigated whether these receptors interact with each other. Coimmunoprecipitation experiments by pulling down FLAGtagged EPHA6 or HA-tagged ALK-2 in TGS-03 and TGS-04 cells showed that overexpressed EPHA6 protein physically interacted with the ALK-2-CA receptor (Figure 4A,B) . Furthermore, binding of EPHA6 to the ALK-2-CA receptor was reduced in the presence of LDN193189 ( Figure 4C ), implying that ALK-2 kinase activity supports binding to EPHA6 and that this interaction is correlated with their cooperative effects in causing apoptosis.
| EPHA6 promotes apoptosis in BMP-2-sensitive TGS-01 cells
TGS-01 cells were used because of their tumor-forming ability in the brain in immunocompromised mice 9 and sensitivity to BMP-2induced apoptosis ( Figure S1D ). BMP-2 signaling alone induced apoptosis in TGS-01 cells infected with ad-LacZ and this effect was augmented by overexpression of EPHA6-WT or EPHA6-KD ( Figure 5A Figure 5C,D, respectively) . In the absence of BMP-2, the WT or KD mutant of EPHA6 alone also showed significant upregulation of apoptosis-related genes compared to the LacZ control ( Figure   S2A ,B, respectively).
Because EPHA6 kinase activity was not shown to be a prerequisite for apoptosis, we further examined the function of EPHA6 binding to ephrin-A ligands by using EPHA6-Fc consisting of the Nterminal ephrin-binding domain conjugated to IgG1. EPHA6 could bind to all ephrin-A ligands (A1-A5) 36 and EPHA6-Fc has been used to block endogenous ephrin-A ligands in the mouse brain. 37 In TGS-01 cells, EPHA6-Fc treatment minimally affected BMP-2induced apoptosis compared to the IgG-Fc control (Figure S2C,D) .
This result suggests a ligand-independent mechanism in addition to the EPHA6 kinase-independent mechanism for the augmented EPHA6/BMP-2 apoptosis activity in GIC.
| EPHA6 gain-of-function suppresses GBM growth in vivo
Tumorigenic abilities of TGS-01 cells overexpressing LacZ control, EPHA6-WT or EPHA6-KD were examined by orthotopic inoculation into nude mice in the presence or absence of BMP-2 pretreatment ( Figure 6 ). BMP-2 pretreatment alone did not delay tumor progression of GIC expressing LacZ; however, EPHA6-KD mutant expression inhibited tumor growth, resulting in extended survival of mice compared to LacZ control ( Figure 6A,B) . This tumor-suppressive effect was enhanced by BMP-2 pretreatment as observed in the survival curve ( Figure 6A ), in agreement with the data obtained in cell culture experiments. TGS-01 cells overexpressing EPHA6-WT with BMP-2 pretreatment also showed smaller tumors and longer survival of mice than the LacZ control with BMP-2 pretreatment (Figure 6C,D) .
Nevertheless, TGS-01 cells overexpressing EPHA6-KD with BMP-2 pretreatment exerted the strongest tumor-suppressive effect compared to both EPHA6-WT and LacZ control ( Figure 6C ,D).
| D ISCUSS I ON
The present study showed that EPHA6 is a pro-apoptotic receptor that interacts with the BMP type I receptor to sensitize cells to BMP-2-induced cell death in apoptosis-responsive or apoptosis-resistant GIC (Figures 1 and 5) . BMP bind to type II and type I receptors. Among the three different BMP type I receptors expressed in glioblastoma cells, we reported that only ALK-2, but not ALK-3 or ALK-6, induced GIC apoptosis, and that knockdown of ALK-2 abolished the apoptosis-inducing activity of BMP-4 and BMP-7, indicating that ALK-2 is responsible for inducing apoptosis in GIC. 9 Although BMP-2 does not directly bind to ALK-2, 38 it may activate ALK-2 by indirectly binding through ALK-3 39 or other coreceptors. BMP also bind to three different type II receptors, namely BMPRII, ActRII/ACVR2A, and ActRIIB/ ACVR2B. 40 Additional studies are needed to determine which after multiple passages of the cells, suggesting that certain signaling pathways were perturbed in these cells. Interestingly, BMPRII was shown to inhibit ALK-2-induced cell death in multiple myeloma cells by blocking ALK-2 oligomerization with type II activin receptors ActRII and ActRIIB, thus reducing ALK-2 activity. 41 Selective BMPRII versus ActRII/IIB binding may also play a role in inducing cytostasis and apoptosis in human GIC. EPHA6 association with ALK-2 might alter its interaction with type II receptors, thus influencing signaling directions and sensitivity to BMP-induced apoptosis.
Bone morphogenetic proteins transduce intracellular signals through SMAD and non-SMAD pathways. 40 For EPHA6 to function as a pro-apoptotic factor in GIC, ALK-2 kinase activity was required for optimum induction of cell death, 9 signal is plotted on Y-axis and Annexin-V signal on X-axis. B-D, TGS-01 cells were infected with ad-LacZ, ad-EPHA6-WT, and ad-EPHA6-KD in the presence or absence of BMP-2 for 24 h and RNA-sequencing analysis was carried out. Genes with fragments per kilobase of exon per million mapped fragments (FPKM) values equal or higher than 3 are selected for gene set enrichment analysis. Plots show enrichment of apoptotic genes in LacZ cells treated with vs without BMP-2 treatment (B), EPHA6-WT vs LacZ-expressing cells (both treated with BMP-2) (C), and EPHA6-KD vs LacZ-expressing cells (both treated with BMP-2) (D). NES, normalized enrichment score the EPHA6 receptor. In agreement with this possibility, EPHA6 was not phosphorylated at tyrosine-925 when EPHA6-KD was transduced into TGS-03 and TGS-04 cells ( Figure 3A) . BMP-regulated decrease of EPHA2 protein levels in GIC 10 may also lead to increased EPHA6 mRNA transcription which contributes to EPHA6 phosphorylation. Accordingly, increase in EPHA6 mRNA transcription could be observed in TGS-04 cells ( Figure S3 ). In the mouse heart, EphA2 deficiency was associated with higher EphA6 expression and reduced cardiomyocyte survival after infarction. 44, 45 In addition to EPHA6, other RTK, including ROR2, MuSK, and TrkC, have been reported to associate with BMP receptors. [46] [47] [48] ROR2 RTK and ALK-6 form a protein complex, leading to transphosphorylation of ROR2 and activation of non-SMAD pathways, 46 whereas MuSK RTK binds to ALK-3 or ALK-6 and stimulates BMP-SMAD signaling independently of its tyrosine kinase activity. 47 EPHA6 kinase activity was not necessary for apoptosis induction ( Figure 3) , and for impeding tumor growth ( Figure 6 ). Effects of EPHA6 on apoptosis are likely to be independent of ephrin ligand binding ( Figure S2 ). Although many Eph receptors are linked to oncogenic functions in GBM, 49 some can cause apoptosis independently of ligand binding or kinase activity. For example, EPHA4 induces cell death in the absence of ephrin-B3 ligand in subventricular zone neuroblasts during adult neurogenesis 50 and in glioblastoma. 51 Furthermore, the intrinsically kinase-inactive EPHB6 promotes breast cancer cell death by anoikis mediated by EPHA2 signaling inhibition 52 and apoptosis through mitochondrial fragmentation, F I G U R E 6 Erythropoietin-producing hepatocellular carcinoma receptor A6 (EPHA6) gain-of-function impedes glioblastoma multiforme tumor growth in a mouse orthotopic model. A, Survival curve of mice inoculated with TGS-01-luc (luciferase) cells infected with ad-LacZ or ad-EPHA6-KD and pretreated or not pretreated with 200 ng/mL BMP-2 for 2 d. n = 4 for all groups except the EPHA6-KD group treated with BMP-2 (n = 3). LacZ + BMP-2 vs EPHA6-KD + BMP-2 (*P < .05); LacZ vs EPHA6-KD (**P < .01). B, Tumor formation shown by luciferase signals in the groups of mice as in experiment (A) at 3 wk-time point. cps, count per second. C, Survival curve of mice inoculated with TGS-01-luc cells infected with ad-LacZ, ad-EPHA6-WT, or ad-EPHA6-KD pretreated with 200 ng/ mL BMP-2 for 2 d. n = 5 for all groups. LacZ + BMP-2 vs EPHA6-WT + BMP-2 (**P < .01); LacZ + BMP-2 vs EPHA6-KD + BMP-2 (**P < .01). (D) Tumor formation shown by luciferase signals in the groups of mice as in experiment (C) at the 3-wk time point. One mouse from LacZ + BMP-2 group was omitted in the survival analysis (C) due to premature death during anesthesia.
rendering cells susceptible to death receptor signaling. 53 c-Kit RTK, which binds to BMPRII, 54 was similarly reported to induce apoptosis in the absence of its ligand and its apoptotic activity was enhanced by the loss of its kinase function. 55 Collectively, our data imply that EPHA6 expression is beneficial for GBM inhibition, particularly in combination with activation of BMP-2 signaling. How this interaction works in vivo remains an unanswered question. These results suggest that EPHA6 expression or protein levels could be used as biomarkers for identification of subsets of GBM patients who might benefit from BMP treatment. Although the levels of EPHA6 expression are lower in brain tumors than in normal brain, BMP-2 induced the expression of EPHA6 mRNA in TGS-04 cells ( Figure S3 ), suggesting that certain signals can induce the expression of EPHA6 in GIC. It is also interesting to investigate whether EPHA6, BMP-2, or ALK-2-CA can be delivered using oncolytic viruses for future GBM treatment. 56 
